Nonpharmacologic Interventions for Reducing Blood Pressure in Adults With Prehypertension to Established Hypertension.
Fu J, Liu Y, Zhang L, Zhou L, Li D, Quan H, Zhu L, Hu F, Li X, Meng S, Yan R, Zhao S, Onwuka JU, Yang B, Sun D, Zhao Y.
J Am Heart Assoc. 2020 Oct 20;9(19):e016804. doi: 10.1161/JAHA.120.016804. Epub 2020 Sep 25.
Role of NLRP-3 Inflammasome in Hypertension: A Potential Therapeutic Target.
Pasqua T, Pagliaro P, Rocca C, Angelone T, Penna C.
Curr Pharm Biotechnol. 2018;19(9):708-714. doi: 10.2174/1389201019666180808162011.
Molecular characterization of alterations in the intestinal microbiota of patients with grade 3 hypertension.
Mushtaq N, Hussain S, Zhang S, Yuan L, Li H, Ullah S, Wang Y, Xu J.
Int J Mol Med. 2019 Aug;44(2):513-522. doi: 10.3892/ijmm.2019.4235. Epub 2019 Jun 6.
Grade of knowledge of hypertension in hypertensive patients.
Estrada D, Sierra C, Soriano RM, Jordán AI, Plaza N, Fernández C; en nombre del equipo investigador.
Enferm Clin (Engl Ed). 2020 Mar-Apr;30(2):99-107. doi: 10.1016/j.enfcli.2018.11.033. Epub 2019 Apr 4.
[Secondary hypertension in women].
Amar L, Azizi M.
Presse Med. 2019 Nov;48(11 Pt 1):1265-1268. doi: 10.1016/j.lpm.2019.07.029. Epub 2019 Nov 13.
Therapeutic Phlebotomy in Patients with Grade 1 Hypertension: A Randomized-Controlled Trial.
Jeitler M, Roth S, Steckhan N, Meier L, Koppold-Liebscher DA, Kandil FI, Ostermann T, Stange R, Kessler CS, Brinkhaus B, Michalsen A.
J Integr Complement Med. 2022 Jun;28(6):530-539. doi: 10.1089/jicm.2021.0396. Epub 2022 Mar 2.
Prognostic impact of hypertension grading.
Angeli F, Verdecchia P, Reboldi G.
Eur J Intern Med. 2024 Aug;126:83-88. doi: 10.1016/j.ejim.2024.04.008. Epub 2024 Apr 14.
The incidence of long-term hypertension in children after high-grade renal trauma.
Fuchs ME, Anderson RE, Myers JB, Wallis MC.
J Pediatr Surg. 2015 Nov;50(11):1919-21. doi: 10.1016/j.jpedsurg.2015.05.014. Epub 2015 Jun 3.
Chinese expert consensus on the management of hypertension in adults with type 2 diabetes.
Pan X, He H, Bao Y, Bi Y, Chen L, Chen X, Fang H, Feng W, Gao L, Guo L, Guo Y, Han Y, Hua Q, Li N, Li Q, Li Y, Li Y, Li X, Liu J, Ma H, Mu J, Nong K, Shang H, Shen Y, Shi Z, Sun F, Sun N, Tao J, Wang J, Wang X, Wu J, Xiao X, Xie L, Xu J, Xu J, Ye H, Yu D, Yuan H, Zhang H, Zhang J, Zhang L, Zhang Y, Zhou J, Zhou X, Zhu D, Zhu T, Li S, Zhu Z; Diabetes and Obesity Research Group of Chinese Diabetes Society (CDS) and Chinese Hypertension League (CHL).
J Evid Based Med. 2024 Dec;17(4):851-864. doi: 10.1111/jebm.12655. Epub 2024 Nov 12.
Incidence and risk of hypertension associated with PARP inhibitors in cancer patients: a systematic review and meta-analysis.
Chen X, Wen Q, Kou L, Xie X, Li J, Li Y.
BMC Cancer. 2023 Jan 31;23(1):107. doi: 10.1186/s12885-023-10571-5.
